Compare Ascendis Pharma A/S (ASND) vs Brown-Forman Corporation Class B (BF.B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Brown-Forman Corporation Class B — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Brown-Forman Corporation Class B trades at $26.26. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.
| ASND | BF.B | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $31.26 |
52-Week Low | $163.32 | $22.80 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BF.B trades at $26.17, up 3.77% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show three beats out of four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst consensus is mixed, with 25% buy, 50% hold, and 25% sell ratings, reflecting cautious optimism amid weak valuation ratio data.
The stock faces headwinds from bearish technical trends and incomplete fundamental metrics, but consistent earnings beats provide a positive catalyst. Risks include market volatility and lack of recent news, while institutional sentiment remains divided. Upside depends on future financial disclosures confirming profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →
